Bristol Cash and Equivalents vs Accounts Payable Analysis
BMY Stock | USD 48.86 0.13 0.27% |
Bristol Myers financial indicator trend analysis is way more than just evaluating Bristol Myers Squibb prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Bristol Myers Squibb is a good investment. Please check the relationship between Bristol Myers Cash And Equivalents and its Accounts Payable accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bristol Myers Squibb. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population.
Cash And Equivalents vs Accounts Payable
Cash and Equivalents vs Accounts Payable Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Bristol Myers Squibb Cash and Equivalents account and Accounts Payable. At this time, the significance of the direction appears to have fragmental relationship.
The correlation between Bristol Myers' Cash and Equivalents and Accounts Payable is 0.5. Overlapping area represents the amount of variation of Cash and Equivalents that can explain the historical movement of Accounts Payable in the same time period over historical financial statements of Bristol Myers Squibb, assuming nothing else is changed. The correlation between historical values of Bristol Myers' Cash and Equivalents and Accounts Payable is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Cash and Equivalents of Bristol Myers Squibb are associated (or correlated) with its Accounts Payable. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Accounts Payable has no effect on the direction of Cash and Equivalents i.e., Bristol Myers' Cash and Equivalents and Accounts Payable go up and down completely randomly.
Correlation Coefficient | 0.5 |
Relationship Direction | Positive |
Relationship Strength | Weak |
Cash And Equivalents
Accounts Payable
An accounting item on the balance sheet that represents Bristol Myers obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Bristol Myers Squibb are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.Most indicators from Bristol Myers' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Bristol Myers Squibb current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bristol Myers Squibb. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population. At this time, Bristol Myers' Sales General And Administrative To Revenue is fairly stable compared to the past year. Enterprise Value Over EBITDA is likely to rise to 12.22 in 2024, whereas Selling General Administrative is likely to drop slightly above 3.6 B in 2024.
2021 | 2022 | 2023 | 2024 (projected) | Gross Profit | 36.4B | 36.0B | 34.3B | 36.0B | Total Revenue | 46.4B | 46.2B | 45.0B | 47.3B |
Bristol Myers fundamental ratios Correlations
Click cells to compare fundamentals
Bristol Myers Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Bristol Myers fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 129.9B | 118.5B | 109.3B | 96.8B | 95.2B | 99.9B | |
Short Long Term Debt Total | 47.5B | 51.7B | 45.6B | 40.7B | 41.5B | 43.5B | |
Other Current Liab | 7.9B | 10.2B | 10.1B | 13.1B | 11.5B | 12.1B | |
Total Current Liabilities | 18.3B | 19.1B | 21.9B | 21.9B | 22.3B | 23.4B | |
Total Stockholder Equity | 51.6B | 37.8B | 35.9B | 31.1B | 29.4B | 15.0B | |
Property Plant And Equipment Net | 6.3B | 6.7B | 7.0B | 7.5B | 8.0B | 5.2B | |
Net Debt | 35.2B | 37.1B | 31.6B | 31.6B | 30B | 31.5B | |
Retained Earnings | 34.5B | 21.3B | 23.8B | 25.5B | 28.8B | 22.0B | |
Cash | 12.3B | 14.5B | 14.0B | 9.1B | 11.5B | 12.0B | |
Non Current Assets Total | 100.6B | 88.3B | 76.1B | 69.5B | 63.4B | 66.6B | |
Non Currrent Assets Other | 6.6B | 2.1B | 1.7B | 1.0B | 1.9B | 2.0B | |
Cash And Short Term Investments | 12.3B | 14.5B | 14.0B | 9.1B | 12.3B | 12.9B | |
Net Receivables | 7.7B | 8.5B | 12.5B | 13.9B | 15.3B | 16.0B | |
Good Will | 22.5B | 20.5B | 20.5B | 21.1B | 21.2B | 22.2B | |
Common Stock Shares Outstanding | 1.7B | 2.3B | 2.2B | 2.1B | 2.1B | 1.6B | |
Liabilities And Stockholders Equity | 129.9B | 118.5B | 109.3B | 96.8B | 95.2B | 99.9B | |
Non Current Liabilities Total | 59.9B | 61.5B | 51.4B | 43.8B | 43.4B | 45.6B | |
Inventory | 4.3B | 2.1B | 2.1B | 2.3B | 2.7B | 1.9B | |
Other Current Assets | 2.0B | 1.4B | 1.3B | 1.6B | 1.5B | 1.8B | |
Other Stockholder Equity | 18.4B | 18.1B | 13.1B | 6.5B | 1.9B | 2.0B | |
Total Liab | 78.2B | 80.6B | 73.3B | 65.7B | 65.7B | 69.0B | |
Property Plant And Equipment Gross | 6.3B | 5.9B | 11.0B | 11.6B | 12.8B | 13.5B | |
Total Current Assets | 29.4B | 30.2B | 33.3B | 27.3B | 31.8B | 33.4B | |
Accumulated Other Comprehensive Income | (1.5B) | (1.8B) | (1.3B) | (1.3B) | (1.5B) | (1.6B) | |
Short Term Debt | 3.5B | 2.5B | 5.1B | 4.4B | 3.3B | 3.4B | |
Intangible Assets | 64.0B | 53.2B | 42.8B | 36.4B | 27.5B | 28.9B | |
Accounts Payable | 2.4B | 2.7B | 2.9B | 3.0B | 3.3B | 1.9B | |
Short Term Investments | 3.0B | 1.3B | 3.2B | 130M | 816M | 775.2M | |
Other Liab | 15.9B | 12.3B | 11.0B | 7.4B | 8.5B | 4.9B | |
Other Assets | 4.8B | 7.3B | 3.3B | 2.9B | 3.3B | 3.3B | |
Long Term Debt | 43.4B | 48.3B | 39.6B | 35.1B | 36.7B | 38.5B | |
Treasury Stock | (25.4B) | (26.2B) | (31.3B) | (38.6B) | (43.8B) | (41.6B) | |
Property Plant Equipment | 6.3B | 5.9B | 6.0B | 6.3B | 7.2B | 5.8B | |
Current Deferred Revenue | 4.5B | 3.6B | 3.7B | 1.3B | 4.2B | 4.4B | |
Net Tangible Assets | (34.9B) | (36.0B) | (28.2B) | (25.9B) | (23.4B) | (22.2B) | |
Noncontrolling Interest In Consolidated Entity | 96M | 100M | 60M | 57M | 55M | 74.7M |
Pair Trading with Bristol Myers
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Bristol Myers position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Bristol Myers will appreciate offsetting losses from the drop in the long position's value.Moving together with Bristol Stock
0.62 | VKTX | Viking Therapeutics Potential Growth | PairCorr |
Moving against Bristol Stock
0.48 | ZURA | Zura Bio Limited Financial Report 10th of May 2024 | PairCorr |
The ability to find closely correlated positions to Bristol Myers could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Bristol Myers when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Bristol Myers - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Bristol Myers Squibb to buy it.
The correlation of Bristol Myers is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Bristol Myers moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Bristol Myers Squibb moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Bristol Myers can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bristol Myers Squibb. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population. You can also try the Content Syndication module to quickly integrate customizable finance content to your own investment portal.
Complementary Tools for Bristol Stock analysis
When running Bristol Myers' price analysis, check to measure Bristol Myers' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bristol Myers is operating at the current time. Most of Bristol Myers' value examination focuses on studying past and present price action to predict the probability of Bristol Myers' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bristol Myers' price. Additionally, you may evaluate how the addition of Bristol Myers to your portfolios can decrease your overall portfolio volatility.
Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
Commodity Directory Find actively traded commodities issued by global exchanges | |
Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
CEOs Directory Screen CEOs from public companies around the world | |
Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
Risk-Return Analysis View associations between returns expected from investment and the risk you assume |
Is Bristol Myers' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bristol Myers. If investors know Bristol will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bristol Myers listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.09) | Dividend Share 2.31 | Earnings Share 3.86 | Revenue Per Share 21.753 | Quarterly Revenue Growth 0.006 |
The market value of Bristol Myers Squibb is measured differently than its book value, which is the value of Bristol that is recorded on the company's balance sheet. Investors also form their own opinion of Bristol Myers' value that differs from its market value or its book value, called intrinsic value, which is Bristol Myers' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bristol Myers' market value can be influenced by many factors that don't directly affect Bristol Myers' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bristol Myers' value and its price as these two are different measures arrived at by different means. Investors typically determine if Bristol Myers is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bristol Myers' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.